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a b s t r a c t
Impairment of nitric oxide (NO) – cyclic GMP signaling pathway is likely to contribute to human begnin
prostate hyperplasia (BPH). In the present study we have used a model of chronic NO synthesis
inhibition to evaluate the functional alterations of prostate smooth muscle (PSM) machinery, and
involvement of Rho-kinase pathway. Wistar rats were treated with the NO inhibitor Nω-nitro-L-arginine
methyl ester (L-NAME, 20 mg/kg/day; 4 weeks), after which contractile responses to phenylephrine
(α1-adrenoceptor agonist; 1 nM to 100 mM), carbachol (muscarinic agonist; 1 nM to 1 mM) and α,β-
methylene ATP (P2X receptor agonist; 1–10 mM), as well as to electrical-ﬁeld stimulation (EFS; 1–32 Hz)
were evaluated. PSM relaxations to isoproterenol (non-selective β-adrenoceptor agonist, 0.1 nM to
10 mM) and sodium nitroprusside (NO donor, 1 nM to 10 mM) were also evaluated. The ratio prostate
weight/body weight was 22% greater (Po0.05) in L-NAME compared with control group. The PSM
contractions to phenylephrine, carbachol and α,β-methylene ATP were higher in L-NAME (Emax:
3.8570.25, 3.5270.35 and 2.0370.2 mN, respectively) compared with control group (Emax:
3.0870.17, 2.3770.18 and 1.5770.18 mN, respectively). The PSM contractions induced by EFS were
also signiﬁcantly greater in L-NAME group. Prior incubation with the Rho-kinase inhibitor Y27632 (1 mM)
fully reversed the enhanced contractions to phenylephrine and carbachol. Isoproterenol-induced PSM
relaxations were 34% lower in L-NAME group, which was associated with reduced levels of cAMP in
prostate tissue. The relaxations to sodium nitroprusside remained unaltered in L-NAME group. In
summary, chronic NO deﬁciency leads to increased Rho-kinase-mediated PSM contractile responses
accompanied by impairment of β-adrenergic-cAMP-signaling pathway.
& 2015 Elsevier B.V. All rights reserved.
1. Introduction
Prostate smooth muscle (PSM) is densely innervated by exci-
tatory sympathetic and parasympathetic autonomic ﬁbers, the
activation of which results in the release of the neurotransmitters
noradrenaline and acetylcholine, respectively (McVary et al., 1998;
Witte et al., 2008). Noradrenaline acting in post-juntional
α1-adrenoceptors (α1-AD) together with acetylcholine acting in
muscarinic M3 receptors (mAChR) produce PSM contractions
mainly via Ca2þ–IP3 signaling-dependent mechanisms (Michel
and Vrydag, 2006; Ventura et al., 2002). Purinergic excita-
tory neurotransmission via functional ligand-gated purinergic
receptors (P21) also produces PSM contractions (Ventura et al.,
2003). Studies have also identiﬁed nitric oxide (NO) produced by
nitrergic nerves as an important inhibitory neurotransmitter
involved in PSM relaxations in animal and human prostate (Di
Iulio et al., 1997; Hedlund, 2005; Kedia et al., 2008). Prostate-
generated NO is mainly produced via neuronal NO synthase
(nNOS) present in nerves and ganglia in the transition zone, and
in prostate epithelium (Bloch et al., 1997). Endothelial NO synthase
(eNOS) has also been found in endothelium and epithelial cells
(Gradini et al., 1999). In benign prostatic hyperplasia (BPH) and
aging, the reductions of nitrergic innervation and NO-mediated
relaxations, together with increased PSM tone have been reported
to contribute to PSM dysfunction (Aikawa et al., 2001; Bloch et al.,
1997; Dey et al., 2012).
Changes in the RhoA/Rho-kinase signaling pathway account for
the increased peripheral vascular resistance that leads to hyperten-
sion (Rao et al., 2013). In the lower urinary tract, including prostate
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(Christ and Andersson, 2007), both α1-adrenoceptor and muscarinic
receptor-mediated PSM contractile responses are regulated by RhoA/
Rho-kinase Ca2þ-senitization pathway, as demonstrated in animal
(Lam et al., 2013; Saito et al., 2011; White et al., 2011, 2013) and
human tissues (Rees et al., 2003; Strittmatter et al., 2011; Takahashi
et al., 2007). Elevated RhoA/Rho-kinase signaling has also been
shown to play a role in BPH (Adam, 2003; Gur et al., 2011). Evidence
shows the existence of a functional antagonism between the Rho-
kinase pathway and the NO/cGMP pathway in vasculature, which has
been clearly demonstrated in the rat model of chronic NO inhibition
(Ikegaki et al., 2001; Ito et al., 2004; Kataoka et al., 2002; Seko et al.,
2003). No previous study, however, has evaluated the effects of
chronic NO inhibition in PSM and its modulation by Rho-kinase. We
hypothesized that Rho-kinase activation under chronic NO deﬁciency
contributes to alterations of PSM contractile machinery. Thus, the
aim of this study was to investigate the rat PSM reactivity to α1-AD,
muscarinic and P2X receptor activation in rats undergoing chronic
NO blockade, and its modulation by Rho-kinase. Since activation of
β-AD leads to PSM relaxations due to activation of adenylate cyclase–
cAMP signaling pathway (Carmena et al., 1997; Kalodimos and
Ventura, 2001), and that activation of α1-AD causes phosphorylation
of β2-AD in the in the human prostate (Hennenberg et al., 2011), this
study also aimed to evaluate the β-AD-mediated PSM relaxations and
cAMP levels in chronic NO-deﬁcient rats.
2. Material and methods
2.1. Animals
All experimental procedures were conducted in accordance
with institutional guidelines, and they were approved by the
Ethical Principles in Animal Research by the Brazilian College for
Animal Experimentation (COBEA). Male wistar rats (initially
weighing 250–300 g) were provided by Central Animal House
Services (CEMIB) of State University of Campinas (UNICAMP, São
Paulo). Animals were housed 5 per cage on 12 h light–dark cycle,
and fed a standard chow diet with water ad libitum.
2.2. L-NAME treatment
Rats that received L-NAME at the dose of 20 mg/rat/day for four
weeks, given in the drinking water, according to previous studies
(Medeiros et al., 1995). Brieﬂy, L-NAME was dissolved in the
drinking water at a concentration of 400 mg/L to give a daily
intake of 20 mg/rat/day. The volume of water drunk by each rat
was approximately 50 ml/rat/day. Control animals received tap
water alone. Systolic blood pressure was recorded weekly by tail-
cuff system using a PowerLab 400™ data acquisition system
(Software Chart, version 4.2, AD Instruments, MA, USA).
2.3. Prostate preparation and concentration–response curves
Animals were anesthetized with halothane and exsanguinated.
Prostate was removed and immediately placed in chilled Krebs
solution of the following composition (mM): NaCl, 118; NaHCO3,
25; glucose, 5.6; KCl, 4.7; KH2PO4, 1.2; MgSO4 7H2O, 1.17 and
CaCl2 2H2O, 2.5. Prostate was dissected and each strip was
mounted under resting tension of 5 mN in 4-ml organ chambers
containing Krebs solution at 37 1C (pH 7.4) and continuously
bubbled with a mixture of 95% O2 and 5% CO2. Isometric force
was recorded using a PowerLab 400™ data acquisition system
(Software Chart, version 6.0, AD Instrument, MA, USA). The tissues
were allowed to equilibrate for 1 h before starting the experi-
ments. Cumulative concentration–response curves to phenyle-
phine (PE; α1-adrenoceptor agonist; 1 nM to 100 mM), carbachol
(CCh; muscarinic receptor agonist; 1 nM to 1 mM) and non-
cumulative curve to α,β-methylene ATP (purinergic P2X agonist;
1, 3 and 10 mM) were constructed by using one-half log unit
increments. Each prostate strip was used to construct only one
concentration–response curve. The maximal response (Emax) and
potency (pEC50) were determined for all tested agonists. Emax was
represented by mN (contraction protocols). Relaxing responses to
isoproterenol (nonselective β-adrenoceptor agonis; 1 nM to
10 mM) and sodium nitroprusside (NO donor; 1 nM to 10 mM)
were also performed in PSM preparations. Relaxing responses
were calculated as percentages of the maximal changes from the
steady-state contraction produced by CCh (10 mM to isoproterenol
relaxation) and PE (10 mM to sodium nitroprusside) in each tissue.
The Emax and pEC50 were also determined.
2.4. Electrical-ﬁeld stimulation (EFS)-induced prostate contractions
Electrical-ﬁeld stimulation (EFS) was applied in prostate strips
placed between two platinum electrodes (3 mm diameter) con-
nected to a Grass S88 stimulator (Astro-Med Industrial Park).
Frequency–response curves (1–32 Hz) were elicited by stimulating
the tissues for 10 s with pulses of 1 ms width at 50 V, with 2 min
interval between stimulations.
2.5. Measurements of cAMP and cGMP levels
Prostate strips were equilibrated for 30 min in warmed and
oxygenated Krebs solution. To quantify cAMP levels, tissues were
stimulated for 4 min with isoproterenol (1 μM) in the absence and
in the presence of the adenylate cyclase inhibitor SQ 22,536
(100 μM, 30 min). Frozen tissues were separately pulverized,
homogenized in trichloroacetic acid (TCA, 5% wt/vol), and centri-
fuged for 10 min at 4 1C at 1500g. The supernatant was collected,
and the pellet was dried and weighted. TCA was extracted from
the supernatant with three washes of water saturated ether.
Preparation of tracer, samples, standards and incubation with
antibody were performed as described in the Kit instructions
(Cayman Chemical Cyclic AMP or Cyclic GMP EIA Kit, Ann Arbor,
MI, USA). The assays were performed in triplicate, and the pellet
weight was used to normalize the data, which were expressed as
pmol/mg tissue.
2.6. Statistical analysis
All data are expressed as means7S.E.M. (n). The program
Instat (GraphPad software) was used for statistical analysis. One-
way ANOVA and unpaired Student's t-test was used to evaluate the
results. Po0.05 was accepted as signiﬁcant.
3. Results
3.1. Tail-cuff pressure, body weight, prostate weight and prostate/
body weight ratio
Four-week treatment with L-NAME (20 mg/rat/day) produced a
signiﬁcant increase (Po0.001) in tail-cuff pressure compared with
control group (Table 1). A small (but signiﬁcant) reduction
(Po0.05) in body weight after L-NAME treatment was observed.
The prostate weight did not change signiﬁcantly between both
groups. The prostate/body weight ratio was 22% greater (Po0.01)
in L-NAME compared with control group (Table 1).
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3.2. Concentration–response curves to PE, CCh, α,β-methylene ATP
and EFS
Addition of PE (1 nM to 100 mM) produced concentration-
dependent prostate contractions in both control and chronic
L-NAME groups (Fig. 1A). However, the Emax was signiﬁcantly
greater in L-NAME compared with control group, whereas the
pEC50 to this α1-adrenoceptor agonist did not change between
groups (Table 2). The muscarinic agonist CCh (1 nM to 1 mM) also
produced concentration-dependent contractile responses in con-
trol and L-NAME groups (Fig. 1B). The Emax and pEC50 values for
CCh were greater in L-NAME compared with control group (Fig. 1B,
Table 2).
In separate prostate preparations, in vitro addition of L-NAME
(100 mM, 30 min) to the organ baths did not signiﬁcantly affect
PSM contractions induced by PE (pEC50: 6.4270.06 and
6.3570.07; Emax: 3.2270.25 and 3.2670.22 mN, for control
and L-NAME, respectively; n¼5) or CCh (pEC50: 5.7070.15 and
5.7270.10; Emax: 2.1670.29 and 2.0870.21 mN, for control and
L-NAME, respectively; n¼8).
Non-cumulative addition of the P2X receptor agonist α,β-
methylene ATP (1, 3 and 10 mM) caused concentration-dependent
PSM contractions that were greater in preparations from chronic
L-NAME compared with those from control rats (Fig. 1C, n¼5–6).
In the control group, EFS (1 to 32 Hz) produced frequency-
dependent PSM contractions, which were signiﬁcantly reduc-
ed (Po0.05) by pre-incubation (30 min) with the non-selective
α-adrenoceptor antagonist phentolamine (10 mM; 43% reduction at
8 Hz stimulation), the muscarinic receptor antagonist atropine
(10 mM; 50% reduction at 8 Hz stimulation) and the purinergic P2X
receptor antagonist PPADS (30 mM; 37% reduction at 8 Hz stimula-
tion). A cocktail of phentolamine, atropine and PPADS reduced
by 470% the EFS-induced contractions (n¼4). In rats treated with
L-NAME, EFS-induced PSM contrations were signiﬁcantly greater at
Table 1
Tail-cuff pressure (TCP), body weight (BW), prostate weight (PW) and BW/PW ratio
after 8 weeks of treatment with Nω-nitro-L-arginine methyl ester (L-NAME, 20 mg/
rat/day, 4 weeks) in rats.
Control L-NAME
TCP (mmHg) 11872 19876.1a
BW (g) 46276 43175b
PW (mg) 381718 434727
PW/BW ratio (mg/g) 82.573.8 100.675.7b
Data are the mean7S.E.M. (n¼10–11 rats).
a Po0.001 compared with respective control group.
b Po0.01.
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Fig. 1. Concentration–response curves to phenylephrine (PE, 1 nM to 100 mM; A), carbachol (CCh, 1 nM to 1 mM; B), α,β-methylene ATP (1, 3 and 10 mM; C) and electrical-ﬁeld
stimulation (EFS, 1–32 Hz; D) in rat prostate smooth muscle preparations obtained from control and L-NAME (Nω-nitro-L-arginine methyl ester)-treated rats (20 mg/rat/day,
4 weeks). Data represent the mean7S.E.M. *Po0.05 and **Po0.001 compared with control group.
Table 2
Potency (pEC50) and maximal responses (Emax) of cumulative concentration–
response curves to phenylephrine (PE; α1-adrenoceptor agonist), carbachol (CCh;
non-seletive muscarinic receptor agonist), isoproterenol (ISO; non-selective
β-adrenoceptor agonist) and sodium nitroprusside (SNP, NO donor compound) in
prostate smooth muscle from control and L-NAME-treated rats. Prostate relaxations
induced by ISO and SNP were expressed relative to the maximal changes from the
contraction produced by carbachol, which was taken as 100%.
Agents Parameters Control L-NAME
PE (n¼9–11) pEC50 6.4970.04 6.7570.11
Emax 3.0870.17 3.8570.25a
CCh (n¼5) pEC50 5.7270.12 6.1470.11a
Emax 2.3770.18 3.5270.35b
ISO (n¼5) pEC50 7.6270.06 7.6270.08
Emax 67.375.56 44.673.75a
SNP (n¼5) pEC50 5.2970.10 5.1470.15
Emax 72.674 75.172.6
Data are the mean7S.E.M. (n¼number of rats in each group).Nω-nitro-L-arginine
methyl ester (L-NAME; 20 mg/rat/day, 4 weeks).
a Po0.05.
b Po0.001 compared with respective control group.
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the frequencies of 1, 2 and 4 Hz compared with control group
(Po0.05; Fig. 1D).
3.3. Relaxant responses to isoproterenol and cAMP levels
The non-selective β-adrenoceptor agonist isoproterenol (1 nM
to 10 mM) produced concentration-dependent PSM relaxations in
both control and L-NAME groups (Fig. 2A). Emax to isoproterenol
was signiﬁcantly lower (Po0.05) in L-NAME compared with
control group, whereas no differences between groups were found
at the level of pEC50 (Table 2).
In control group, incubation of prostate tissues with isoproter-
enol (1 mM) elevated by 13-fold the cAMP levels above baseline
(Po0.001; n¼3). A signiﬁcant reduction (Po0.05) in the cAMP
levels was found in prostate tissues obtained from L-NAME-
treated rats (Fig. 2B). Prior incubation of prostate tissues with
the adenylate cyclase inhitor SQ22535 (100 mM) markedly reduced
the isoproterenol-induced cAMP elevations in both control and
L-NAME groups.
3.4. Effect of the Rho-kinase Y27632 in the PSM hypercontractility of
L-NAME-treated rats
PSM preparations from both control and L-NAME treated rats
were pre-treated with Y27632 (1 mM, 30 min) before performing
concentration–response curves to PE or CCh.
In concentration–response curves to PE in control group,
pretreatment with Y27632 signiﬁcantly reduced the pEC50 (shift
of 4.3) with any effects in the Emax value (Fig. 3A and B; Table 3). In
L-NAME group, Y27632 produced a markedly higher right dis-
placement in PE-induced contractions (shift of 7.8) with a con-
comitant normalization of the Emax value (Fig. 3A and B; Table 3).
In concentration–response curves to CCh in control group,
Y27632 did not signiﬁcantly affect pEC50 (shift of 1.4; P¼0.5) and
Emax values (P¼0.078) (Fig. 3C and D; Table 3). However, in L-NAME
group, Y27632 produced a marked right displacement (shift of 3.5)
with a signiﬁcant reduction in Emax (Fig. 3C and D; Table 3).
3.5. PSM relaxant responses to sodium nitroprusside
The NO donor sodium nitroprusside (1 nM to 10 mM) produced
concentration-dependent PSM relaxations in both control and L-
NAME groups. However, no signiﬁcant differences between groups
were found for this compound at the levels of pEC50 or Emax
(Fig. 2C, Table 2). Basal cGMP levels in prostate tissues of L-NAME
group were 43% lower (Po0.05) than the control group (470.4
and 771 fmol/mg, respectively), conﬁrming the efﬁcacy of
chronic L-NAME treatment.
4. Discussion
This study shows that chronic NO deﬁciency causes greater
PSM contractions to α1-AD and muscarinic activation, which are
fully prevented by the Rho-kinase inhibitor Y27632, indicating an
important role for the Rho-kinase signaling pathway in mediating
the prostate hypercontractility. Signiﬁcant reductions of β-AD-
induced PSM relaxations and cAMP levels were also observed in
chronic NO-deﬁcient rats, which may contribute to the state of
prostate hypercontractility.
The cardiovascular alterations caused by long-term NO deﬁ-
ciency are well documented. Chronic NO deﬁciency also promotes
bladder overactivity as result of increased contractile responses to
muscarinic receptor activation and reduced β3-AD-mediated relaxa-
tions, which is restored by stimulation of soluble guanylate cyclase
(Mónica et al., 2008, 2011). Most of functional studies addressing to
examine the role of NO on PSM reactivity have employed in vitro
addition of NO inhibitors to isolated organ baths in electrically-
stimulated prostate preparations (Najbar-Kaszkiel et al., 1997;
Takeda et al., 1995). However, no similar studies attempting to
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Fig. 2. Concentration–response relaxing curves to the non-selective β-adrenoceptor agonist isoproterenol (ISO; A) and cAMP contents (B) in prostate smooth muscle
obtained from control and L-NAME (Nω-nitro-L-arginine methyl ester)-treated rats (20 mg/rat/day, 4 weeks). Panel C shows the concentration–response curves to the nitric
oxide donor sodium nitroprusside (SNP). For measurement of cAMP contents, prostate tissues were stimulated with ISO (1 mM) in absence and presence of the adenylate
cyclase inhibitor SQ22,536 (100 mM, 30 min). Data represent the mean7S.E.M. #Po0.001 compared with respective basal levels; δPo0.05 compared with ISO-stimulated
prostate tissues in control group; *Po0.05 and **Po0.001 compared with respective ISO-stimulated tissues in absence of SQ22,536.
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evaluate the PSM contractile responses to α1-AD, muscarinic and
P21 activation from rats treated chronically with NO inhibitors
have been carried out. Studies addressing to evaluate the relaxant
machinery secondary to activation of cAMP and cGMP in prostate in
conditions of chronic NO deprivation have also been neglected. In
the present study, we show that PSM contractions induced by PE,
CCh and α,β-methylene ATP are signiﬁcantly greater in chronic
L-NAME compared with control group, as evaluated at both potency
(pEC50) and/or efﬁcacy (Emax). Electrically-stimulated contractile
PSM responses, which results mainly from the release of noradrena-
line, acetylcholine and ATP (Najbar-Kaszkiel et al., 1997), were also
greater in L-NAME group, reinforcing our data with direct receptor
activation. Interestingly, however, addition of L-NAME to the organ
bath (100 mM) failed to affect CCh- and PE-induced contractions,
indicating that long-term rather than acute NO inhibition accounts
for the functional PSM alterations.
Activation of α1-AD and muscarinic elicits phosphoinositide (PI)
hydrolysis and hence generation of the second messenger IP3 that
activates the IP3 receptor to release Ca2þ from internal stores
(Somlyo and Somlyo, 2003). The state of Ca2þ-dependent phos-
phorylation of myosin light chain kinase (MLCK) is further regulated
by myosin phosphatase, an enzyme tightly regulated by RhoA and
its downstream target Rho-kinase, as evidenced in different smooth
muscle types, including prostate (Christ and Andersson 2007; Saito
et al., 2011; Takahashi et al., 2007). A physiological antagonism
between Rho-kinase pathway and NO has been clearly described in
vascular smooth muscle (Kolluru et al., 2014), but no such antagon-
ism has been explored in PSM. In our study, a Rho-kinase inhibitor
Y27632 fully prevented the enhanced PE and CCh-induced PSM
contractions in L-NAME group, restoring the Emax to control levels.
This ﬁnding indicates that RhoA/Rho-kinase pathway plays a key
role in the enhanced agonist-induced PSM contractions in condi-
tions of prolonged NO inhibition. Of note, the increased α,β-
methylene ATP-induced contractions in rat detrusor, trigonal and
urethral smooth muscles have also been associated with Rho-kinase
pathway (Teixeira et al., 2007).
Prostate relaxations mediated by activation of β-AD-cAMP play
a key role to the maintenance of the physiological tonus of PSM
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Fig. 3. Prostate smooth muscle contractions in response to the α1-adrenoceptor agonist phenylephrine (PE; A and B) and muscarinic receptor agonist carbachol (CCh; B
and D) in the absence and in the presence of the Rho-kinase inhibitor Y27632 (1 mM) in control and L-NAME (Nω-nitro-L-arginine methyl ester)-treated rats (20 mg/rat/day,
4 weeks). Data represent the means7S.E.M. nPo0.05 compared with control group, ##Po0.01 and ###Po0.001 compared with L-NAME group without Y27632.
Table 3
Potency (pEC50) and maximal responses (Emax) of cumulative concentration–response curves to phenylephrine (PE) and carbachol (CCh) in prostate smooth muscle
preparations in the absence and in the presence of the Rho kinase inhibitor Y27632 (1 mM) in control and L-NAME-treated rats.
Groups PE CCh
pEC50 Shift Emax pEC50 Shift Emax
Control 6.4370.07 3.1070.27 5.7170.09 2.2770.17
ControlþY27632 5.8070.12a 4.3 3.0070.19 5.5670.18 1.4 1.5570.34
L-NAME 6.6370.10 4.1270.32b 6.0770.11 3.5570.31a
L-NAMEþY27632 5.7470.10c 7.8 2.6170.13d 5.5370.11e 3.5 1.7170.20c
Data are the mean7S.E.M. (n¼5–6 rats).
Shift, arithmetic multiple for change in potency
Nω-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat/day, 4 weeks).
a Po0.001 compared with respective control group.
b Po0.05.
c Po0.001 compared with L-NAME group.
d Po0.01.
e Po0.05.
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(Michel, 2011). Recently, the selective β3-AD agonist mirabegron
was shown to counteract the human and rabbit PSM contractions
induced by EFS and α1-AR activation, highlighting a potential use
of this compound in BPH treatment (Calmasini et al., 2014). In
our study, the PSM relaxant response to the non-selective β-AD
receptor agonist isoproterenol was signiﬁcantly lower in L-NAME-
treated rats, which was accompanied by lower stimulated cAMP
production in the prostate tissues. A previous study in human
prostate reported that activation of α1-adrenoceptor leads to β2-
adrenoceptor phosphorylation and consequent desensitization
(Hennenberg et al., 2011). It is likely therefore that the increased
contractile responses to EFS in L-NAME group reﬂect an augment
in noradrenaline release, leading to β-AD phosphorylation with
consequent impairment in cAMP production. Further investiga-
tions will be needed to conﬁrm this hypothesis. Nitric oxide has
been shown to downregulate the noradrenaline release from
sympathethic neurons (Schwarz et al., 1995), which may also
explain our data showing augmented EFS-induced contractions
in L-NAME group.
The NO-cGMP-PDE5 pathway also plays an important role in
producing PSM relaxations, the impairment of which results in BPH
(Hedlund, 2005). Accordingly, PDE5 inhibitors have been success-
fully used to treat this condition (Oelke et al., 2012). In our study,
the PSM relaxations to the NO donor sodium nitroprusside were not
signiﬁcantly changed by the chronic L-NAME treatment, indicating
that the intracellular relaxant machinery downstream NO remains
unaffected by chronic L-NAME treatment.
Benign prostate enlargement and the resulting bladder outﬂow
obstruction in humans have been linked with lower urinary tract
symptoms, including urgency with or without urge-incontinence,
and increases in frequency and nocturia. Rats under prolonged
L-NAME administration develop a marked arterial hypertension, but
to our knowledge the reactivity of PSM in animal models of
hypertension other than chronic L-NAME has not been explored
in literature. In addition, a small (but signiﬁcant) increase in
prostate weight/body weight (PW/BW) ratio was detected in
L-NAME group. However, this increased PW/BW ratio may not be
considered a relevant prostate enlargement when compared with
the classical model of testosterone in rats (Oudot et al., 2012). Thus,
it is unlikely that increased PW/BW ratio in our study contributes to
the PSM dysfunction in chronic L-NAME-treated rats.
In summary, rats treated chronically with the NO synthesis
inhibitor L-NAME present PSM dysfunction as evidenced by the
greater Rho kinase-dependent contractions to α1-AD and mus-
carinic receptor activation along with lower relaxations secondary
to β-AD–cAMP pathway activation.
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